Lexicon Pharma (LXRX) Misses Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.04 +0.99%
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $320 thousand versus the consensus estimate of $133.33 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- The Fed is hiking. Why isn't UBS worried about stocks?
- Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
